The FDA recently approved a new ORAL therapy, Jascayd (nerandomilast) from Boehringer Ingelheim, indicated for idiopathic pulmonary fibrosis (IPF) in adult patients. IPF is a rare, progressive disease with no cure and limited treatment options. No other therapy has been approved for IPF in more than a decade.
Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease, deadlier than several common cancers, with most patients dying within five years of diagnosis. It mainly affects adults over 50, especially men, and is marked by symptoms such as persistent cough and shortness of breath. The cause is unknown, and about 200,000 people in the U.S. are affected.
CLICK HERE to access prescribing information
The company confirmed the list price of Jascayd at $16,219 per month.
The company did not announce plans for logistics /distribution. Given that it is an ultra-rare, high-cost oral therapy it is strongly felt that Jascayd will be available via specialty pharmacy limited distribution.
FDA approves drug to treat idiopathic pulmonary fibrosis
